Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

- Halneuron^® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track as projected for Q4 2025 -

- Low discontinuation rate (6%) due to adverse events amongst the first 35 patients completing the trial suggests Halneuron^® and placebo treatment have been generally well tolerated -

Read more at globenewswire.com